Sutro Biopharma
STRO
119 hedge funds and large institutions have $185M invested in Sutro Biopharma in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 58 increasing their positions, 28 reducing their positions, and 19 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 28
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
2% more funds holding
Funds holding: 117 → 119 (+2)
0.83% less ownership
Funds ownership: 8.55% → 7.72% (-0.83%)
39% less capital invested
Capital invested by funds: $302M → $185M (-$117M)
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $91K
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.6M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$7.63M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.06M |
| 4 |
BlackRock
New York
|
+$4.78M |
| 5 |
EP
Eversept Partners
New York
|
+$2.56M |
Top Sellers
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$4.16M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.49M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.93M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$1.59M |
| 5 |
Millennium Management
New York
|
-$1.48M |
STRO Hedge Fund Activity: Q2 2024 in Review
119 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2024, worth a combined $185M — down 39% from $302M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new STRO positions and 19 closed out — a net gain of 2 holders — while 58 added to existing stakes and 28 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $16.6M. The largest seller was MPM BioImpact, cutting an estimated $4.16M.
- 119 institutional investors held Sutro Biopharma (STRO) as of Q2 2024, up from 117 in Q1 2024.
- Funds reported $185M of Sutro Biopharma stock for Q2 2024, down 39% quarter-over-quarter.
- 21 funds opened new Sutro Biopharma positions in Q2 2024 and 19 closed out, a net change of +2 holders.
- The largest Sutro Biopharma buyer in Q2 2024 was Point72 Asset Management, an estimated $16.6M added.
- The largest Sutro Biopharma seller in Q2 2024 was MPM BioImpact, an estimated $4.16M sold.
Based on aggregated 13F filings for Q2 2024.